Fusion Pharmaceuticals’ Post

The promise of nuclear medicine is finally being realized. (pre)clinical data is pouring in with exceptional responses of tumors to treatment and this is igniting the imagination of a future where cancer diagnosis and treatment is guaranteed! #nuclearmedicine

Some exciting news coming yesterday from Fusion Pharmaceuticals!

🌐 Collaboration for ADC Development: Samsung Biologics Partners with LegoChem Biosciences 🌐 Exciting news in the biopharmaceutical industry! Samsung Biologics and LegoChem Biosciences have teamed up to develop and manufacture ADC therapies. This partnership marks a significant collaboration in the field and has the potential to shape the future of ADC therapies. I am curious to hear your thoughts on this collaboration. How do you think this partnership will impact the biopharmaceutical landscape? Share your thoughts in the comments below! #ADCTherapies #BiopharmaceuticalCollaboration #InnovationPartnership

The demand for high-concentration monoclonal antibody (mAb) production is escalating rapidly in the biopharmaceutical industry. This increasing requirement introduces several process-related bottlenecks that necessitate modifications across multiple production steps. It is essential that these processes work in concert to ensure the consistent delivery of a high-quality bulk drug substance. Cytiva has developed innovative solutions aimed at addressing the challenges associated with producing high-concentration mAb drug substances, facilitating more efficient and scalable manufacturing processes. https://lnkd.in/eivy8eNx

Unlocking Cost-Efficiency in Commercial Antibody Biopharmaceutical Manufacturing Are you looking to reduce the cost of therapeutic antibody production? Read our white paper to learn how switching to our game-changing #continuousbiomanufacturing platform leads to the cost-effective production of antibody biologics. Download the white paper: https://hubs.ly/Q02HsyD00 Featuring: • Our J.POD facility design concept overview • Cost-modelling using BioSolve software • A cost-sensitivity analysis • Recursive dynamic programming calculation of facility metrics Feel free to comment below with your thoughts or any questions. #costmodelling #continuousbiomanufacturing #JustEvotecBiologics #researchneverstops

Accelerate speed-to-market for heat sensitive drugs, including biologics. Monoclonal antibodies and other heat-sensitive biopharmaceuticals may rely on lyophilization to dry compounds without heat. Lyophilization is a complex process that poses tech transfer and scale-up challenges. Here’s how data driven approaches can accelerate process optimization and shorten time-to-market. https://bit.ly/42bKHcp

FUJIFILM Corporation plans a ¥700 billion ($4.5 billion) investment by 2028 to expand its biopharmaceutical contract manufacturing business globally. This includes $1.2 billion for equipment at a North Carolina plant. The aim is to increase production capacity to 750,000 liters by 2028. Fujifilm competes with Lonza, WuXi Biologics, and Samsung Biologics and expects sector sales to surpass ¥500 billion by March 2029. The biopharmaceutical market is projected to grow to $27.9 billion by 2029. Fujifilm entered the sector in 2011, with total investments expected to exceed ¥1 trillion ($6.5 billion). #Biopharmaceutical #Manufacturing #Growth #Innovation #Transformation #Business #Finance #Japan I Nikkei Asia

LOTTE BIOLOGICS is delighted to announce the release of a new video outlining our mid-to-long-term strategic plans. This comprehensive overview underscores our unwavering commitment to driving innovation, sustainability, and growth within the biopharmaceutical industry.     🔍 Key Insights from the Video:  • LOTTE BIOLOGICS' Vision: Explore our long-term vision for the future of biopharmaceuticals and how we aim to shape the industry landscape.  • Syracuse Bio Campus Advantages: Learn about the distinct benefits of our Syracuse Bio Campus, offering fully integrated solutions for antibody production and ADC conjugation at a single, state-of-the-art location.  • Songdo Bio Campus Development: Gain insights into the construction timeline and advanced capabilities of our Songdo Bio Campus, designed for high-titer biopharmaceutical production.  • Partnership Opportunities: Understand the compelling reasons to partner with LOTTE BIOLOGICS and how collaborative efforts can foster mutual success. 📺 Watch the Video Here: https://lnkd.in/g5hGt2aX We encourage our valued partners, stakeholders, and followers to watch the video and gain a deeper understanding of LOTTE BIOLOGICS' exciting future. Your continued support and collaboration are vital as we embark on this transformative journey towards excellence and innovation. #LOTTEBIOLOGICS #Biopharmaceuticals #Innovation #Sustainability #StrategicVision #CDMO #ADC 

In this exclusive guidebook, discover the journey of a molecule & how it's built to serve. Merck experts share key considerations for biopharmaceutical companies as they advance their antibody drug to commercial manufacturing, plus more. Don't miss out! Learn More>> https://hubs.li/Q02NRXZg0 Sponsored by Merck

🇩🇪 Germany has emerged as a powerhouse in the global biopharmaceutical landscape, driven by robust investments in R&D, supportive regulations, and a rich ecosystem of industry players. Our research team is proud to present a new ebook, Empowering Biologics for Commercial Success: Science, Technologies, Partners. This ebook is released in conjunction with Biologics Manufacturing Germany 2024. It provides a comprehensive overview of the latest trends in Germany's biopharmaceutical market, including: - Germany's Biopharmaceutical Market Ascendancy - Past Technologies vs. Innovative Solutions in Germany - Collaborative Ecosystem for Innovation - Major Players in Germany 📚 For further information, download the ebook to review market trends and growth opportunities in Germany: https://lnkd.in/edZhr_52